Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 placebo-controlled study of obicetrapib in ASCVD with inadequately controlled lipids
NL-OMON59116Phase 3Active, not recruiting
- Sponsor
- NewAmsterdam Pharma
- Start
- Jun 2022
- Modality
- Classical Binding Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease and hypercholesterolemia comparing Obicetrapib 10 mg with Placebo (2 arms). Primary endpoint: MACE-4 time to first event. Started Jun 2022; status: active, not recruiting.
02
Drugs
obicetrapib
03
Conditions
atherosclerotic diseasehypercholesterolemia
Beyond the preview
Go deeper on NL-OMON59116.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59116.